Eli Lilly and Company LLY

1,183.46 1.57 0.13% as of 25 Sep
Market cap
$1.11T
P/E
39.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Eli Lilly and Company (LLY) EV/Sales

As of 25 September 2026, Eli Lilly and Company (LLY) trades at a EV/Sales of 13.8×. Over the past ten years it has ranged from 3.6× (December 2016) to 23.5× (June 2024); the current reading is higher than 77% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 15.3× (4.28%)
FY2024 16.0× (0.73%)
FY2023 16.1× 34.24%
FY2022 12.0× 29.21%
FY2021 9.3× 37.42%
FY2020 6.8× 11.64%
FY2019 6.1× 7.98%
FY2018 5.6× 23.28%
FY2017 4.6× 18.94%
FY2016 3.8× (17.80%)

Quarterly

Period EV/Sales Change
Jun 2026 14.0× 17.93%
Mar 2026 11.9× (22.52%)
Dec 2025 15.3× 26.38%
Sep 2025 12.1× (12.23%)
42 more quarters

Against its own ten years

Low 3.6× High 23.5×
Ten-year median 7.0×
Current reading's percentile 77

EV/Sales against peers

Company EV/Sales
PFE Pfizer Inc. compare 3.4×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
MRK Merck & Co., Inc. compare 6.2×
JNJ Johnson & Johnson compare 6.8×
GILD Gilead Sciences, Inc. compare 6.9×
AMGN Amgen Inc. compare 7.0×
ABBV AbbVie Inc. compare 8.3×
LLY Eli Lilly and Company 13.8×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LLY